Table 2 Changes in parameters assessed on imaging, pre- and post- rituximab
From: Use of rituximab in idiopathic retroperitoneal fibrosis
Parameter: | Pre-Rituximab Treatment No. (%) | Post-Rituximab Treatment No. (%) | P Value |
|---|---|---|---|
Thickness of RPF Massa (mm) | 16.1 ± 4.6 | 10.4 ± 6.2 | 0.01 |
Craniocaudal RPF Lengtha (mm) | 108.6 ± 40.4 | 90.6 ± 45.9 | 0.02 |
Presence of Hydronephrosis | 7/10 (70) | 4/10 (40) | 0.37 |
Unilateral | 5/10 | 3/10 | |
Bilateral | 2/10 | 1/10 | |
Presence of Renal Atrophy (unilateral) | 5/10 (50) | 6/10 (60) | 1 |
Presence of Renal Stents | 1/10 (10) | 4/10 (40) | 0.3 |
Unilateral | 1/10 | 3/10 | |
Bilateral | 0/10 | 1/10 | |
Ureter Involvement | 10/10 (100) | 10/10 (100) | 1 |
Unilateral | 3/10 | 5/10 | |
Bilateral | 6/10 | 5/10 | |
Renal Vessel Involvement | 3/10 (30) | 3/10 (30) | 1 |
Unilateral | 1/10 | 2/10 | |
Bilateral | 2/10 | 1/10 | |
Common Iliac Vessel Involvement | 10/10 (100) | 10/10 (100) | 1 |
Unilateral | 1/10 | 2/10 | |
Bilateral | 9/10 | 8/10 | |
Imaging Type | |||
CT | 10/10 | 9/10 | |
MRI | 0/10 | 1/10 | |